American Society of Hematology 57th Annual Meeting, Orlando FL, December 5-8, 2015 – Brand-name drugs are new therapies (or “me-too” drugs) that are rigorously tested before they are allowed on the market by regulatory bodies, such as the U.S. Food and Drug Administration or Hea
A new goal in treating CML is treatment-free remission (TFR). What this means is that CML is so deeply suppressed with treatment that the person is able to stop the medication altogether and the leukemia doesn’t return. The physical advantages of TFR will be obvious to anyone taking o
It’s not always a simple matter to get access to the medications you need, but a delay in starting treatment for CML can jeopardize the success of therapy. This was shown in a recent study conducted in Bosnia, where people often face considerable red tape before they can start a
Chronic myelogenous leukemia is a hot area of medical research, in part because of the development of the first effective treatment (Gleevec) a decade ago and the insights about the biology of the disease that have resulted from that important discovery.
CML was once considered a death sentence, with people typically living only a few years after being diagnosed. But have TKI medications, such as Gleevec, Sprycel, Tasigna or Bosulif, actually made a difference?
Many people with CML start treatment with a second-generation medication, such as Sprycel or Tasigna, because they more potently suppress the proliferation of leukemia cells. But how do these two medications compare?
Report from the American Society of Clinical Oncology (ASCO), Chicago IL, May 29-June 2, 2015 – Bosulif (bosutinib) is one of the more recent TKIs used for the treatment of CML. It’s a potent drug that is generally kept in reserve for people with an inadequate response or poor t